Cases & Deals

  • Home
  • Practices
  • Celgene defends its leading product Revlimid® against patent revocation actions in UK

Share

Celgene defends its leading product Revlimid® against patent revocation actions in UK

August 2018

Client(s) Celgene Corporation

Jones Day acted for Celgene Corporation in multiple cases brought by Accord Healthcare in the UK High Court (patents court) in relation to Celgene's patents concerning its best-selling drug, Revlimid®.

Accord Healthcare Limited v. Celgene Corporation, HP 2017 000036, 000038 (UK High Court)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.